The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma Group (Inst); AstraZeneca (Inst); Bayer (Inst); Biodesix (Inst); Boston Biologics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); Janssen (Inst); Laekna Therapeutics (Inst); Lilly (Inst); LSK BioPharma (Inst); Mirati Therapeutics (Inst); MT Group (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncopeptides (Inst); Pfizer (Inst); Polynoma (Inst); Seagen (Inst); Syneos Health (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Ultimovacs (Inst); Vaccinex (Inst); Zeno Pharmaceuticals (Inst)
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Consulting or Advisory Role - AbbVie (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunomet (Inst); Mekanistic Therapeutics (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ryvu Therapeutics (Inst); Sotio (Inst); Trillium Therapeutics (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
 
James Andrew Reeves
Consulting or Advisory Role - Karyopharm Therapeutics
Speakers' Bureau - Eisai; Janssen Oncology
Research Funding - Sarah Cannon Research Institute (Inst)
 
Meredith McKean
Consulting or Advisory Role - Array BioPharma (Inst); AstraZeneca (Inst); Pfizer (Inst); Regeneron (Inst)
Research Funding - Ascentage Pharma Group (Inst); Bicycle Therapeutics (Inst); Dragonfly Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Novartis (Inst); Oncorus (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst)
 
Bartosz Chmielowski
Consulting or Advisory Role - Deciphera; Epizyme; Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; OncoSec; Sanofi
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Deciphera; Epizyme; Regeneron
 
Joseph Thaddeus Beck
No Relationships to Disclose
 
Montaser F. Shaheen
No Relationships to Disclose
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Bayer; Bayer; Blueprint Medicines; Deciphera; Immune Design
Research Funding - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; MedImmune
 
Melissa Wilson
No Relationships to Disclose
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Gritstone Bio; incyte; Jazz Pharmaceuticals; Merck (Inst); Mirati Therapeutics; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Takeda (Inst); Trovagene (Inst)
 
Joseph J. Drabick
Consulting or Advisory Role - Sanofi/Aventis
 
Yuefen Tang
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Robert Winkler
Employment - Ascentage Pharma
 
Mingyu Li
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Mohammad Ahmad
Employment - Ascentage Pharma
 
Ming Lu
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
ZHIYAN LIANG
Employment - Ascentage Pharma
Stock and Other Ownership Interests - Ascentage Pharma
 
Dajun Yang
Employment - Ascentage Pharma; Ascentage Pharma Group (I); HealthQuest Pharma; HealthQuest Pharma (I)
Leadership - Ascentage Pharma; Ascentage Pharma (I); HealthQuest Pharma; HealthQuest Pharma (I)
Stock and Other Ownership Interests - Ascentage Pharma; Ascentage Pharma (I)
Research Funding - Sun Yat-sen University; Sun Yat-sen University (Inst)
Patents, Royalties, Other Intellectual Property - Ascentage Pharma; Ascentage Pharma (I)
Travel, Accommodations, Expenses - Ascentage Pharma; Ascentage Pharma (I); HealthQuest Pharma; HealthQuest Pharma (I)
 
Yifan Zhai
Employment - Ascentage Pharma
Leadership - Ascentage Pharma; Ascentage Pharma (I)
Stock and Other Ownership Interests - Ascentage Pharma; Ascentage Pharma (I)
Research Funding - Ascentage Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Ascentage Pharma; Ascentage Pharma (I); Ascentage Pharma (Inst)